Cambridge Nuclear Radiopharmaceutical
Country not established
- Devices
- 1
What Cambridge Nuclear Radiopharmaceutical makes
Cambridge Nuclear Radiopharmaceutical manufactures Calcitonin 125, a radiopharmaceutical used for diagnostic imaging and bone metabolism studies.
The product is classified as Class II under FDA regulations and is listed via 510(k) clearance. The company operates from the United States.
Catalogue
Calcitonin 125 Ref K781909
Regimes: 510(k) Registry: 510(k)
Frequently asked questions
How many devices does Cambridge Nuclear Radiopharmaceutical have in the registry?
The registry currently lists 1 device for Cambridge Nuclear Radiopharmaceutical. Devices recorded under merged duplicate company entries are counted once.
Which registries list Cambridge Nuclear Radiopharmaceutical's devices?
Among its 1 most recently registered device, Cambridge Nuclear Radiopharmaceutical has devices listed in FDA 510(k) (1 device).
What risk classes do Cambridge Nuclear Radiopharmaceutical's devices fall under?
Among its 1 most recently registered device, the classes recorded for Cambridge Nuclear Radiopharmaceutical's devices are Class II. Each device page shows its own class and authorisation.
What are the newest devices from Cambridge Nuclear Radiopharmaceutical in the registry?
The most recently registered devices listed for Cambridge Nuclear Radiopharmaceutical include CALCITONIN 125.